WO2006021347A3 - Diagnostics et therapeutiques pour des maladies associees au recepteur 3c de 5-hydroxytryptamine (5-ht3c) - Google Patents

Diagnostics et therapeutiques pour des maladies associees au recepteur 3c de 5-hydroxytryptamine (5-ht3c) Download PDF

Info

Publication number
WO2006021347A3
WO2006021347A3 PCT/EP2005/008870 EP2005008870W WO2006021347A3 WO 2006021347 A3 WO2006021347 A3 WO 2006021347A3 EP 2005008870 W EP2005008870 W EP 2005008870W WO 2006021347 A3 WO2006021347 A3 WO 2006021347A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
ht3c
therapeutics
diagnostics
diseases associated
Prior art date
Application number
PCT/EP2005/008870
Other languages
English (en)
Other versions
WO2006021347A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Andreas Geerts filed Critical Bayer Healthcare Ag
Publication of WO2006021347A2 publication Critical patent/WO2006021347A2/fr
Publication of WO2006021347A3 publication Critical patent/WO2006021347A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur un 5-HT3c humain associé à des maladies cardio-vasculaires, des maladies endocrinologiques, des maladies métaboliques, au cancer, à des inflammations, à des maladies gastro-entérologiques, des maladies hématologiques, des maladies squeletto-musculaires, des maladies neurologiques, des maladies urologiques, des maladies respiratoires. Cette invention concerne des dosages pour l'identification de composés utiles au traitement ou à la prévention de maladies cardio-vasculaires, de maladies endocrinologiques, de maladies métaboliques, du cancer, des inflammations, des maladies gastro-entérologiques, des maladies hématologiques, des maladies squeletto-musculaires, des maladies neurologiques, des maladies urologiques, des maladies respiratoires. Cette invention porte aussi sur des composés qui se lient et/ou activent ou inhibent l'activité de 5-HT3c, ainsi que sur des compositions pharmaceutiques contenant ces composés.
PCT/EP2005/008870 2004-08-26 2005-08-16 Diagnostics et therapeutiques pour des maladies associees au recepteur 3c de 5-hydroxytryptamine (5-ht3c) WO2006021347A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04020241 2004-08-26
EP04020241.8 2004-08-26

Publications (2)

Publication Number Publication Date
WO2006021347A2 WO2006021347A2 (fr) 2006-03-02
WO2006021347A3 true WO2006021347A3 (fr) 2006-06-15

Family

ID=35355500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/008870 WO2006021347A2 (fr) 2004-08-26 2005-08-16 Diagnostics et therapeutiques pour des maladies associees au recepteur 3c de 5-hydroxytryptamine (5-ht3c)

Country Status (1)

Country Link
WO (1) WO2006021347A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365370B1 (en) * 1999-09-01 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding a human subunit 5-HT3-C of the 5-HT3 serotonin receptor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365370B1 (en) * 1999-09-01 2002-04-02 Ortho-Mcneil Pharmaceutical, Inc. DNA encoding a human subunit 5-HT3-C of the 5-HT3 serotonin receptor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KARNOVSKY A M ET AL: "A cluster of novel serotonin receptor 3-like genes on human chromosome 3", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER, AMSTERDAM, NL, vol. 319, 13 November 2003 (2003-11-13), pages 137 - 148, XP004471828, ISSN: 0378-1119 *
NIESLER B ET AL: "Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E", GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, ELSEVIER, AMSTERDAM, NL, vol. 310, 22 May 2003 (2003-05-22), pages 101 - 111, XP004430571, ISSN: 0378-1119 *

Also Published As

Publication number Publication date
WO2006021347A2 (fr) 2006-03-02

Similar Documents

Publication Publication Date Title
WO2006027147A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur d'adrenomedulline (amdr)
WO2005093092A3 (fr) Diagnostic et traitement de maladies associees au recepteur 44 couple aux proteines g (gpr44)
WO2005106012A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 1 (dpp1)
WO2006010517A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la proteine d'activation des fibroblastes (fap)
WO2006005469A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre les maladies associees au recepteur de glucagon (gcgr)
WO2005103684A3 (fr) Diagnostics et methodes therapeutiqeus pour des maladies associees au recepteur 1 de la chimiokine cx3c
WO2006021343A3 (fr) Diagnostic et therapie de maladies associees au recepteur 3a de la 5-hydroxytryptamine (5-ht3a)
WO2005076007A3 (fr) Diagnostics et traitements de maladies associees au recepteur p2y12 couple a la proteine g (p2y12)
WO2005113786A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees a la chymase (cma1)
WO2005101001A3 (fr) Methodes diagnostiques et therapeutiques pour lutter contre des maladies associees au recepteur couple a la proteine g, element c, groupe 5, famille c (gprc5c)
WO2005093091A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 26 couple a la proteine g (gpr26)
WO2005113788A3 (fr) Diagnostics et therapeutiques pour des maladies associees a la kinase 6 associee au recepteur couple a une proteine g (grk6)
WO2006005470A3 (fr) Agents diagnostiques et therapeutiques pour des maladies associees au recepteur couple a la proteine g lie au mas (mrge)
WO2005073729A3 (fr) Diagnostic et traitement de maladies associees au recepteur p2y11 couple a une proteine g (p2y11)
WO2005101011A3 (fr) Agents diagnostiques therapeutiques pour des maladies associees a lxr-alpha (lxra)
WO2005106486A3 (fr) Diagnostics et therapeutiques de maladies associees a la dipeptidyl-peptidase 3 (dpp3)
WO2005031345A3 (fr) Diagnostic et therapeutique de maladies associees au recepteur couple a la proteine g adipor2 (adipor2)
WO2006040047A3 (fr) Diagnostics et therapeutiques pour des maladies associees a la kinase citron agissant sur rho/rac
WO2006013014A3 (fr) Diagnostics et therapeutiques pour maladies liees a une proteine similaire a un antigene membranaire specifique de la prostate (psmal)
WO2006010515A3 (fr) Diagnostic et traitement therapeutique des maladies associees a la 5-hydroxytryptamine 2a (5ht2a)
WO2005075983A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees a un recepteur nucleaire humain nr4a3 (nr4a3)
WO2006021347A3 (fr) Diagnostics et therapeutiques pour des maladies associees au recepteur 3c de 5-hydroxytryptamine (5-ht3c)
WO2005119263A3 (fr) Diagnostic et traitement des maladies associees au recepteur couple aux proteines g 92 (gpr92)
WO2006005461A3 (fr) Diagnostic et traitement des maladies associees au recepteur 27 couple aux proteines g (rcpg 27)
WO2006013015A3 (fr) Diagnostics et therapeutique pour maladies liees a la marapsine (mpn)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05773121

Country of ref document: EP

Kind code of ref document: A2